Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dalia, Samir
NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays	Recruiting	N/A	160	US	Observation	Tempus AI	Colorectal Cancer	02/25	02/27
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study	Recruiting	N/A	813	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/25	02/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer	Recruiting	N/A	1050	Europe, US	Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay	Razor Genomics, Encore Clinical	Non-Small Cell Lung Cancer	05/24	05/25
Maguire, Kevin
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24